Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AstraZeneca

< Previous 1 2 3 4 5 6 7 Next >
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study
From AstraZeneca
Via Business Wire
Tickers AZN
CALQUENCE reduced the risk of disease progression or death by 71% vs. standard of care combinations at three years in the ASCEND Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Additional Analyses Further Reinforce Ground-breaking Efficacy in Patients With HER2-positive Metastatic Breast Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
Inaugural Asia Summit on Global Health successfully explores healthcare landscape
From AstraZeneca
Via ACN Newswire
Inaugural Asia Summit on Global Health opens today
From AstraZeneca
Via ACN Newswire
Inaugural Asia Summit on Global Health highlights Hong Kong's advantages
From AstraZeneca
Via ACN Newswire
EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care
From AstraZeneca
Via Business Wire
Tickers AZN
LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
New Analyses of Two AZD7442 COVID-19 Phase III Trials in High-Risk Populations Confirm Robust Efficacy and Long-Term Prevention
From AstraZeneca
Via Business Wire
Tickers AZN
LOKELMA® Granted Fast Track Designation in the US to Reduce Cardiovascular Outcomes in Patients on Chronic Hemodialysis With Hyperkalemia
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca Advances Ambition to Redefine Care for Blood Cancer at ASH 2021
From AstraZeneca
Via Business Wire
Tickers AZN
SAPHNELO Consistently Reduces Systemic Lupus Erythematosus Disease Activity Regardless of Disease Duration and Prior Treatment
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca Awards 30 Nonprofit Organizations through the ACT on Health Equity Community Solutions Challenge to Actively Address Health Disparities
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI Plus Chemotherapy Significantly Improved Overall Survival in 1st-Line Advanced Biliary Tract Cancer in TOPAZ-1 Phase III Trial at Interim Analysis
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca and Bob Harper Unveil the Survivors Have Heart Second Chance Portraits to Change the Face of Heart Attack Survivorship
From AstraZeneca
Via Business Wire
AstraZeneca Announces Winners and Recognizes Oncology Change Makers in Third Annual Cancer Community Awards
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI Plus Tremelimumab Significantly Improved Overall Survival in HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis
From AstraZeneca
Via Business Wire
Tickers AZN
AZD7442 Request for Emergency Use Authorization for COVID-19 Prophylaxis Filed in US
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Granted Breakthrough Therapy Designation in US for Patients with HER2-Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based Regimens
From AstraZeneca
Via Business Wire
Tickers AZN
AstraZeneca COVID-19 and RSV presentations at IDWeek 2021 will showcase scientific progress in infectious diseases
From AstraZeneca
Via Business Wire
Tickers AZN
LYNPARZA® (olaparib) in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in 1st-line metastatic castration-resistant prostate cancer
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
From AstraZeneca
Via Business Wire
Tickers AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable response in patients with HER2-positive advanced gastric cancer in DESTINY-Gastric02 Phase II trial
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
IMFINZI and tremelimumab with chemotherapy improved progression-free survival by 28% and overall survival by 23% in 1st-line Stage IV non-small cell lung cancer vs. chemotherapy
From AstraZeneca
Via Business Wire
Tickers AZN
Fixed-Dose Combination of Albuterol and Budesonide (PT027) Demonstrated Significant Benefits for Asthma Patients in MANDALA and DENALI Phase III Trials
From AstraZeneca
Via Business Wire
Tickers AZN
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.